For adeno-associated viral gene therapies to scale, scientists must first address safety and manufacturability challenges. Improving payload design and optimizing production systems can help scientists address those challenges and ensure the safety, efficacy, and scalability of their therapies. In this webinar, Mark Stockdale will discuss how the application of synthetic biology and artificial intelligence can be used to improve the safety, potency and manufacturability of gene therapies, and introduce AAV Edge, a comprehensive platform for end-to-end gene therapy optimization—from payload design to production cell lines and model-guided processes.
Key topics that will be covered in the webinar include:.